PBMWW
OtherPsyence Biomedical Ltd - Warrants (25/01/2029)
Live · NASDAQ · May 9, Close
What's Moving PBMWW Today?
No stock-specific AI insight has been generated for PBMWW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
PBMWW News
16 articles- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceYahoo Finance·Apr 20, 2026
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineYahoo Finance·Apr 17, 2026
- Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV AgreementYahoo Finance·Apr 14, 2026
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical ActivitiesYahoo Finance·Apr 8, 2026
- Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabsYahoo Finance·Nov 12, 2025
- Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative CareYahoo Finance·Nov 6, 2025
- Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On InvestmentYahoo Finance·Nov 3, 2025
- Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine ProductionYahoo Finance·Sep 2, 2025
- Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025Yahoo Finance·Aug 28, 2025
- Corporate Update, August 2025Yahoo Finance·Aug 4, 2025
- Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionYahoo Finance·Jul 31, 2025
- PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesYahoo Finance·Jun 25, 2025
- PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesYahoo Finance·Jun 18, 2025
- Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025Yahoo Finance·Jun 18, 2025
- Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsYahoo Finance·Jun 17, 2025
- Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialYahoo Finance·May 27, 2025
All 16 articles loaded
Price Data
Fundamentals
Trading
About Psyence Biomedical Ltd - Warrants (25/01/2029)
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.